Pimecrolimus reduced the ConA‐induced release of IL‐2 in tissue from non‐IBD patients (22‐fold) and tissue from IBD patients (14‐fold), indicating efficient inhibition of T cell activation ex vivo (Figure 3C). Here, IL2 is linked to inflammatory bowel disease.